Pharma Nachrichten

Zeit	Aktuelle Nachrichten Sprache: Alle DE EN	Leser	Medien
22:36	GSK bets big on cancer comeback with aggressive trial push	2	Seeking Alpha
17:35	GSK sees blockbuster potential in targeted cancer therapy after promising early data	5	Reuters
17:26	GSK reports promising early results in ovarian and womb cancer drug trial	2	Guardian
17:06	AbbVie's Phase 2 Trial Shows 62.7% Response With Mirvetuximab In Platinum-Sensitive Ovarian Cancer	399	AFX News	WASHINGTON (dpa-AFX) - AbbVie (ABBV) reported promising results from the Phase 2 IMGN853-0420 trial evaluating mirvetuximab soravtansine-gynx (ELAHERE) in combination with carboplatin, followed... ► Artikel lesen
15:12	Notable healthcare headlines for the week: Organon, Eli Lilly, and Gilead in focus	8	Seeking Alpha
13:34	Studie: Eierstockkrebs-Medikament von AbbVie zeigt 62,7 % Ansprechrate	22	Investing.com Deutsch
13:30	AbbVie ovarian cancer drug shows 62.7% response rate in trial	5	Investing.com
10:38	BAYER AG - Stabilität als strategische Zwischennote	13	Maximilian Berger
08:30	Bayer unter massivem Druck: Warum Insider bereits still und leise verkaufen - Was Sie vor Montag noch wissen müssen		Hebelschein-Spekulant
Sa	Key deals this week: Organon, UMG, Whitestone REIT, Gilead and more	13	Seeking Alpha
Sa	New to The Street to Broadcast on Fox Business on Monday, April 13, Featuring Virtuix Holdings, Medicus Pharma, YY Group Holdings, Vivos Therapeutics, and Stardust Power	761	ACCESS Newswire	The show will air as sponsored programming nationwide at 10:30 PM PST on Fox Business Network NEW YORK CITY, NY / ACCESS Newswire / April 11, 2026 / New to The Street, one of the longest-running U.S.... ► Artikel lesen
Sa	Eli Lilly Isn't Replacing Zepbound -- It's Building an Obesity Empire	26	The Motley Fool
Sa	Abbott ordered to pay $70M in damages in Chicago baby formula case	4	Seeking Alpha
Sa	New to The Street Broadcasts on Bloomberg Television at 6:30 PM EST Featuring IGC Pharma, Vivos Therapeutics, Acurx Pharmaceuticals, and Equinox Gold	838	ACCESS Newswire	Special continuing M&A Segment with Senior M&A Partner at Sullivan & Cromwell LLP, Frank Aquila NEW YORK CITY, NY / ACCESS Newswire / April 11, 2026 / New to The Street announces its latest nationally... ► Artikel lesen
Sa	Vergessene Biotech-Chance: Kann Aquestive Therapeutics vor dem Durchbruch stehen?	550	ARIVA.de	Aquestive Therapeutics steht trotz operativer Fortschritte und potenziell wertvoller Pipeline unter massivem Bewertungsdruck. Die Aktie notiert deutlich unter früheren Kursniveaus, während sich fundamentale... ► Artikel lesen
Sa	Prognose massiv erhöht - Wird der australische Psychodelika-Spezialist Bioxyne zum neuen Branchenliebling?		Small- & Micro Cap Investment
Sa	Lupin Launches Anti-Diabetic Tablets In The US Market Following USFDA Approval	4	The Free Press Journal
Sa	Zyus Life Sciences Corp: Zyus's first tranche of placement to be final tranche	1	Stockwatch
Sa	ZYUS Life Sciences Provides an Update on Its Unit Offering	1	CNW
Sa	Ayr Wellness Inc: Ayr Wellness closes exit facility with Arboretum	2	Stockwatch

Zeit

Aktuelle Nachrichten

Sprache: Alle DE EN

Leser

Medien

22:36

GSK bets big on cancer comeback with aggressive trial push

Seeking Alpha

17:35

GSK sees blockbuster potential in targeted cancer therapy after promising early data

Reuters

17:26

GSK reports promising early results in ovarian and womb cancer drug trial

Guardian

17:06

AbbVie's Phase 2 Trial Shows 62.7% Response With Mirvetuximab In Platinum-Sensitive Ovarian Cancer

399

AFX News

WASHINGTON (dpa-AFX) - AbbVie (ABBV) reported promising results from the Phase 2 IMGN853-0420 trial evaluating mirvetuximab soravtansine-gynx (ELAHERE) in combination with carboplatin, followed...
► Artikel lesen